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Abstract 
Background: IL-33, which is known to induce type 2 immune responses via group 2 innate lymphoid cells, has been 
reported to contribute to neutrophilic airway inflammation in chronic obstructive pulmonary disease. However, its 
role in the pathogenesis of emphysema remains unclear.
Methods: We determined the role of interleukin (IL)-33 in the development of emphysema using porcine pancreas 
elastase (PPE) and cigarette smoke extract (CSE) in mice. First, IL-33−/− mice and wild-type (WT) mice were given PPE 
intratracheally. The numbers of inflammatory cells, and the levels of cytokines and chemokines in the bronchoalveolar 
lavage (BAL) fluid and lung homogenates, were analyzed; quantitative morphometry of lung sections was also per-
formed. Second, mice received CSE by intratracheal instillation. Quantitative morphometry of lung sections was then 
performed again.
Results: Intratracheal instillation of PPE induced emphysematous changes and increased IL-33 levels in the lungs. 
Compared to WT mice, IL-33−/− mice showed significantly greater PPE-induced emphysematous changes. No differ-
ences were observed between IL-33−/− and WT mice in the numbers of macrophages or neutrophils in BAL fluid. The 
levels of hepatocyte growth factor were lower in the BAL fluid of PPE-treated IL-33−/− mice than WT mice. IL-33−/− 
mice also showed significantly greater emphysematous changes in the lungs, compared to WT mice, following 
intratracheal instillation of CSE.
Conclusion: These observations suggest that loss of IL-33 promotes the development of emphysema and may be 
potentially harmful to patients with COPD.
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Background
Chronic obstructive pulmonary disease (COPD) is char-
acterized by airflow obstruction that is not fully revers-
ible, leading to respiratory insufficiency and functional 
disability [1, 2]. Existing therapeutic options for COPD 
can reduce the severity of symptoms, and the frequency 
and severity of exacerbations. However, these therapies 
have poor efficacy for maintaining lung function and 
palliating symptoms in COPD [1]. Therefore, new anti-
inflammatory therapeutic strategies are required.
The pathogenesis of COPD remains unclear. It has 
been reported that macrophages, neutrophils, and T lym-
phocytes play important roles in the development and 
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progression of emphysematous lung disease in humans. 
In contrast, human hepatocyte growth factor (HGF) has 
been reported to confer protection against the destruc-
tion of alveoli [3–5]; vascular endothelial growth factor 
(VEGF) signaling has also been reported to play a role in 
the maintenance of alveolar structures [6]. These obser-
vations suggest that determining the balance between 
destructive and protective factors in the lung is impor-
tant to understand the pathogenesis of COPD and 
develop new therapeutic options for this disease.
Interleukin (IL)-33 is a member of the IL-1 family [7]. 
IL-33 not only induces type 2 immune response via group 
2 innate lymphoid cells (ILC2s), stimulating basophils 
and eosinophils without an acquired immune response, 
but also induces proinflammatory cytokines, such as 
TNFα, IL-1β, and IL-6, via basophils and mast cells, and 
the Th1 cytokine IFN-γ via natural killer (NK) cells and 
NK T cells [7, 8].
The expression of IL-33 was reported to be increased in 
bronchial endothelial cells in a murine model of COPD 
[9]. IL-33 was shown to induce the expression of IL-6 
and IL-8 following cigarette smoke extract (CSE) expo-
sure [9]. Cigarette smoke (CS) has also been reported 
to induce bronchial epithelium-derived IL-33, and to 
decrease the expression of ST2 (the receptor of IL-33) 
on ILC2s and increase its expression on macrophages 
and NK cells [10]. Treatment with anti-IL-33 antibody 
has been reported to inhibit CS-induced airway inflam-
mation [11]. These data suggest that IL-33 has important 
roles in the development of CS-induced airway inflam-
mation, although its role in the development of emphyse-
matous changes in the lung remains to be clarified.
The present study was performed to investigate the 
susceptibility of IL-33-deficient (IL-33−/−) mice to por-
cine pancreas elastase (PPE) and CSE, to clarify the role 
of IL-33 in the pathogenesis of emphysema.
Methods
Animals and experimental protocol
Female C57BL/6J mice were purchased from Charles 
River Japan, Inc. (Yokohama, Japan).  IL33−/− mice were 
generated as described by Yasuda et  al. [12]. All ani-
mal experiments were performed in accordance with 
the guidelines of the Institutional Animal Care and Use 
Committee of Okayama University Medical School 
(Okayama, Japan).
Elastase‑induced emphysema model
To generate an elastase-induced emphysema model, 
female  IL33−/− mice (8–10  weeks old) and wild-type 
(WT) mice received 2.0 or 3.75 U of PPE by intratracheal 
instillation on day 0 [13]. Control mice received 40 µl of 
phosphate-buffered saline (PBS) at the same time point. 
The mice were sacrificed on days 0, 2, 4, 7, 14, and 21 to 
evaluate lung histology, lung function, airway inflamma-
tion, and the levels of cytokines and chemokines.
Determination of static lung compliance
A flexiVent small-animal ventilator (SCIREQ, Montreal, 
QC, Canada) was used to assess static lung compliance 
(Cst), which is a measure of the elasticity of the lung. Cst 
was calculated from the pressure volume curves using 
flexiVent software (version 5.0; SCIREQ), as described 
previously [14]. Briefly, the mice were anesthetized by 
intraperitoneal injection of 150  mg/kg of ketamine and 
10  mg/kg of xylazine (Kyoritsu Seiyaku, Tokyo, Japan). 
The mice were tracheostomized with a 5-mm section 
of metallic tubing (18 G cannula) and ventilated at 150 
breaths/min with a tidal volume of 10 ml/kg and positive 
end-expiratory pressure of 3  cmH2O. The Cst was then 
measured.
Bronchoalveolar lavage (BAL) fluid
Lungs were lavaged with Hanks’ balanced salt solution 
via the tracheal tube (2 × 1  ml, 37  °C), and the cells in 
BAL fluid were counted. Cytospin slides were stained and 
differentiated in a blinded manner by counting at least 
200 cells under a light microscope, as described previ-
ously [15].
Lung histology and morphometric measurements 
of airspace size
The left lung was inflated by intratracheal instillation of 
10% formalin at a static pressure of 20  cmH2O and fixed 
in 10% formalin. The tissue was then embedded in par-
affin and 2-µm-thick sections were stained with hema-
toxylin and eosin (H&E). The mean linear intercept (Lm), 
which represents the average size of alveoli, was calcu-
lated by counting lines of a defined length, as described 
previously [16–18].
Measurement of cytokines and chemokines
The cytokine levels in the BAL fluid and supernatants of 
homogenized lungs were measured by enzyme-linked 
immunosorbent assay (ELISA), as described previously 
[19]. For preparation of lung homogenates, lung tis-
sue was frozen at − 70  °C immediately after euthanasia. 
The lung tissue was mixed with 0.1% Triton-X100 solu-
tion in PBS containing proteinase inhibitors at a 1:2.5 
ratio of weight per volume (Sigma-Aldrich, St. Louis, 
MO, USA). The specimens were homogenized and then 
centrifuged at 21,480×g for 30  min. The supernatants 
were frozen at − 80 °C until analysis. The limits of detec-
tion were 2  pg/ml for keratinocyte-derived chemokine 
(KC), 2.0  pg/ml for monocyte chemoattractant pro-
tein-1 (MCP-1), 1.5 pg/ml for macrophage inflammatory 
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protein-2 (MIP-2), 12.1  pg/ml for HGF, 3.0  pg/ml for 
VEGF, and 0.014  ng/ml for matrix metalloproteinase-9 
(MMP-9) (R&D Systems, Minneapolis, MN, USA).
Lung cell isolation
Lungs of PPE-treated mice were placed in PBS contain-
ing heat-inactivated 10% FCS. Lung tissue was minced 
and incubated for 1 h at 37 °C in 5 ml of PBS containing 
0.05% collagenase I (Sigma-Aldrich), and then dispersed 
by passing through a 20 G needle several. The suspen-
sions were strained through a cell strainer. The pulmo-
nary mononuclear cells were isolated by density gradient 
cell centrifugation over Histopaque (Sigma-Aldrich) [20].
Flow cytometry
Analyses of ILC2s
The cells isolated from digested lungs were stained with 
biotin-conjugated antibody mixtures for lineage mark-
ers (CD4, CD5, CD8, CD11c, CD11b, CD19, NK1.1, 
Gr-1, TER119, FcεRI, and B220), Pacific blue-conjugated 
anti-Sca-1, PECy7-conjugated c-Kit (CD117), APC-con-
jugated anti-IL-7Rα (CD127), FITC conjugated anti-T1/
ST2, APC-Cy7-conjugated anti-CD25, and PE conjugated 
anti-streptavidin, and analyzed using a MACSQuant 
Analyzer (Miltenyi Biotec, Bergisch Gladbach, Ger-
many).  Lin−Sca+c-Kit+IL-7R+CD25+ST2dim cells were 
identified as lung ILC2s [21, 22]. The data were analyzed 
using FlowJo (TreeStar, Ashland, OR, USA). APC-Cy7-
conjugated anti-CD25, Pacific blue-conjugated anti-
Sca-1, biotin-conjugated anti-CD4, anti-CD5, anti-CD8, 
anti-CD11b, anti-NK1.1, anti-Gr-1, anti-TER119, and 
anti-B220, and PE-conjugated anti-streptavidin antibod-
ies were obtained from BD Biosciences (Franklin Lakes, 
NJ, USA). FITC-conjugated anti-T1/ST2 was from MD 
Bioscience (St Paul, MN, USA). APC-conjugated anti-
IL-7Rα and biotin-conjugated anti-FcεRI antibodies were 
from BioLegend (San Diego, CA, USA). PECy7-conju-
gated c-Kit was from eBioscience (La Jolla, CA, USA). 
Biotin-conjugated anti-CD11c and anti-CD19 were from 
TONBO Biosciences (San Diego, CA, USA).
IL‑33 receptor ST2 blockade with anti‑ST2 antibody
WT mice received PPE or PBS via intratracheal instilla-
tion on day 0. The mice received an intraperitoneal injec-
tion of 100 µg anti-ST2 antibody (R&D Systems) on days 
1, 3, 6, and 9. Control mice received 100 µg rat-IgG (R&D 
Systems) at the same time points. Lung function and lung 
histology were evaluated on day 21.
Administration of recombinant IL‑33 (rIL‑33)
WT mice received PPE or PBS by intratracheal instilla-
tion on day 0. The mice received an intraperitoneal injec-
tion of 1000 ng of rIL-33 (R&D Systems) on days 0 and 
3. Control mice received PBS at the same time points. 
Lung function and lung histology were evaluated on day 
21. In some experiments,  IL33−/− mice received an intra-
peritoneal injection of 1000  ng rIL-33 on day 0 follow-
ing intratracheal instillation of PPE or PBS. Control mice 
received PBS at the same time point. BAL was performed 
on day 2, and the levels of HGF and VEGF in BAL fluid 
were measured.
CSE‑induced emphysema model
CSE was prepared using the 3R4F Kentucky reference 
cigarette. One non-filtered cigarette was burned; the 
smoke was passed through 8 ml of PBS using a vacuum 
pump with a constant air flow of 2 l/min. The extract was 
used when pH was between 6.2 and 6.4 and the optical 
density at 320 nm  (OD320) was between 1.600 and 1.900. 
The extract was freshly prepared for each experiment and 
administered after the pH had been adjusted between 
7.00 and 7.40 and the solution had been filtered through 
a 0.2-μm pore-size filter to remove particles and bacteria 
[14].
The experimental mice received 40 µl of CSE intratra-
cheally on days 0, 7, and 14. Control mice received 40 µl 
of PBS at the same time points. The mice were sacrificed 
on day 21 to evaluate lung histology. In some experi-
ments, the mice received 400 µl of CSE intraperitoneally 
on days 0, 7, 14, and 21. The control mice received 400 µl 
of PBS at the same points. The mice were sacrificed on 
day 28 to evaluate lung histology [14].
Statistical analysis
All results are presented as the mean ± standard error 
of the mean (SEM). Groups were compared by one-way 
analysis of variance (ANOVA). Pairs of samples with a 
parametric distribution were compared by unpaired two-
tailed Student’s t test, and samples with a nonparametric 
distribution were compared by the Mann–Whitney U 
test. In all analyses, P < 0.05 was taken to indicate statisti-
cal significance.
Results
IL‑33 levels in the lung are increased following PPE 
instillation
We first examined whether administration of PPE 
affected the levels of IL-33 in the lung. We measured the 
kinetics of IL-33 in the lung homogenate of PPE-instilled 
WT mice by ELISA (Fig.  1a). The levels of IL-33 in the 
lung were significantly increased on days 4 and 7 fol-
lowing instillation of PPE compared to those on day 0 
(Fig. 1b).
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Development of elastase‑induced emphysema is enhanced 
in IL‑33−/− mice
We assessed lung function to clarify the role of IL-33 in 
the development of elastase-induced emphysema. Cst 
values were higher in PPE-instilled WT mice than in 
saline-instilled WT or IL-33−/− mice on day 21. The Cst 
value was significantly higher in PPE-instilled IL-33−/− 
mice than PPE-instilled WT mice (Fig. 2a). Lung histol-
ogy indicated airspace enlargement and alveolar wall 
destruction in PPE-instilled WT mice (Fig.  2b). These 
emphysematous changes were markedly increased in 
PPE-instilled IL-33−/− mice (Fig.  2b). To further assess 
the development of emphysema, we monitored airspace 
enlargement by determining the Lm in H&E-stained tis-
sue sections. Lm values in PPE-instilled WT mice were 
significantly increased compared to saline-instilled WT 
mice. These changes in PPE-instilled IL-33−/− mice were 
significantly enhanced compared to those in PPE-instilled 
WT mice on days 7 and 14 (Fig. 2c). The results of these 
histological analyses suggested that IL-33−/− mice have 
increased susceptibility to elastase-induced emphysema 
compared to WT controls.
Elastase‑induced airway inflammation in WT and IL‑33−/− 
mice
Airway inflammation is thought to be a major contribu-
tor to the development of emphysema [20]. We assessed 
the severity of the inflammatory response by measuring 
cell accumulation in BAL fluid at different time points 
(Fig. 3a). In WT mice, the recruitment of inflammatory 
cells into airways was increased following instillation 
of PPE (Fig.  3b). The total number of cells in BAL fluid 
was increased largely due to increased numbers of neu-
trophils and macrophages from day 2 to day 21 (Fig. 3c 
and d). There was no significant difference in the number 
of these cells between PPE-instilled WT mice and PPE-
instilled IL-33−/− mice.
Cytokine and chemokine levels in BAL fluid
To further determine the mechanisms underlying the 
increased susceptibility of PPE-instilled IL-33−/− mice 
to PPE-induced emphysema, we measured the levels of 
neutrophil- and macrophage-related chemokines and 
proteinases related to the destruction of alveoli [13, 20, 
23], as well as HGF and VEGF, which protect against the 
development of emphysema [5, 6], in BAL fluid at differ-
ent time points. The levels of KC and MCP-1 were sig-
nificantly increased in PPE-instilled WT mice compared 
to PBS-instilled mice on days 2 and 4 (Fig.  4a and b). 
The levels were also increased in PPE-instilled IL-33−/− 
mice on day 2, but were significantly lower than in PPE-
instilled WT mice on day 4. The levels of MIP-2 and 
MMP-9 were not different between IL-33−/− mice and 
WT mice following PPE instillation (Fig. 4c and d). The 
levels of HGF and VEGF were significantly increased 
in PPE-instilled WT mice compared to those in PBS-
instilled mice on days 2 and 4 (Fig. 4e and f ). The levels 
of HGF in PPE-instilled IL-33−/− mice were significantly 
reduced compared to PPE-instilled WT mice on day 4. 
The levels of VEGF in PPE-instilled IL-33−/− tended to be 
lower on day 4, but the difference between the two strains 
of mice was not significant.
ILC2s in lung tissue
IL-33 is a cytokine that recruits ILC2s into the airway. 
We examined whether ILC2s play an important role in 
PPE-induced emphysema. As shown in Fig.  2b, the lev-
els of IL-33 in lung homogenates were increased follow-
ing PPE instillation on day 7 in our murine model. We 
counted the ILC2s in the lung on day 7. The number of 
ILC2s tended to be higher in PPE-instilled IL-33−/− mice 
compared to PPE-instilled WT mice, but the difference 
was not significant (Fig. 5).
Treatment with anti‑ST2 antibody in PPE‑instilled mice
We assessed whether blockade of the IL-33 receptor, 
ST2, affected PPE-induced emphysema in WT mice. 
Administration of anti-ST2 antibody did not affect 
the Cst values or the MLI values in PPE-instilled mice 
(Additional file  1:   Fig. S1). Although complete loss of 
IL-33 may enhance the development of emphysema, 
Fig. 1 Kinetics of IL-33 in the lungs of porcine pancreas elastase 
(PPE)-treated WT mice. a Experimental protocol. b Kinetics of IL-33 in 
the lung. The results for each group are shown as the mean ± SEM; 
n = 7–9 in each group. *P < 0.05 compared to naïve mice. Day 0 
indicates the group without PPE instillation
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partial blockade of IL-33 does not appear to promote 
emphysematous changes in the lung.
Treatment with rIL‑33 does not reduce emphysema 
in PPE‑instilled mice
As loss of IL-33 enhances emphysematous changes, 
we examined whether IL-33 had a protective effect on 
PPE-induced emphysema in WT mice. The Cst values 
did not decrease following administration of rIL-33 
to mice that received PPE (Fig.  6a). Emphysematous 
changes in lung pathology were unaffected (Fig.  6b). 
These data suggest that although complete loss of IL-33 
enhances the development of emphysema, IL-33 itself 
may not protect against the development of emphyse-
matous changes in the lung.
rIL‑33 treatment increased HGF levels in the airway 
of PPE‑instilled IL‑33−/− mice
The HGF levels in PPE-instilled IL-33−/− mice were sig-
nificantly lower than PPE-instilled WT mice. Thus, we 
examined whether rIL-33 treatment increased HGF lev-
els in IL-33−/− mice. The mice treated with rIL-33 had 
higher HGF levels in BAL fluid than mice treated with 
PBS following PPE instillation (Fig. 7a). The VEGF levels 
in BAL fluid of rIL-33-treated mice were not significantly 
different from those of PBS-treated mice (Fig. 7b). These 
data suggest that IL-33 induced HGF secretion in the 
airway.
CSE‑induced emphysema is enhanced in IL‑33−/− mice
Animal models of emphysema induced by CS or CSE 
more accurately represent emphysematous disease in 
humans than those in which emphysema is induced by 
PPE. We further assessed whether the emphysematous 
changes in IL-33−/− mice were enhanced in the CSE-
induced emphysema model. We have recently reported 
that intraperitoneal injection of CSE induces emphy-
sematous changes in rat [17] and mice [14]. Following 
intraperitoneal injection of CSE, IL-33−/− mice showed 
significantly enhanced emphysematous changes com-
pared WT mice (Additional file 2:  Fig. S2a–c).
We next assessed the ability of intratracheal CSE to 
induce emphysematous changes in the lung (Fig.  8a). 
Airspace enlargement and alveolar wall destruction were 
observed in intratracheally CSE-treated WT mice in lung 
histology. These emphysematous changes were signifi-
cantly increased in CSE-treated IL-33−/− mice compared 
to CSE-treated WT mice (Fig.  8b). Lm values in CSE-
treated WT mice were significantly increased compared 
to saline-treated WT mice. These changes in CSE-treated 
IL-33−/− mice were significantly enhanced compared to 
those in CSE-treated WT mice on day 21 (Fig. 8c). These 
histological observations indicated that IL-33−/− mice 
are more susceptible to CSE-induced emphysema than 
WT mice.
Discussion
IL-33 is a member of the IL-1 family, which acts as a 
ligand for ST2 (IL-1Ra) [7] and induces not only type 2 
cytokines, but also proinflammatory cytokines, such 
as IL-1β, IL-6, and TNF-α, from mast cells [24–27] and 
basophils [8], as well as the type-1 cytokine IFN-γ from 
NK cells and NKT cells [28, 29]. These proinflamma-
tory cytokines, together with Th1-related immunity, 
play important roles in the pathogenesis of COPD [30]. 
Treatment with anti-IL-33 antibody has been reported 
to inhibit CS-induced airway inflammation [11]. These 
studies suggested that IL-33 is involved in the pathogen-
esis of COPD, especially airway inflammation. However, 
the role of IL-33 in the development of emphysematous 
changes in the lung remains to be elucidated.
In the present study, to clarify the role of IL-33 in the 
development of emphysematous changes in the lung, we 
investigated both PPE- and CSE-induced emphysematous 
changes in the lungs of IL-33−/− and WT mice, as well 
as the kinetics of cytokines and chemokines in the lung. 
Our results demonstrated that airspace enlargement of 
the lung was significantly enhanced in IL-33−/− mice 
compared to WT mice, in both PPE and CSE-induced 
emphysema models. There was no significant difference 
(See figure on next page.)
Fig. 2 Assessment of PPE-induced emphysema in IL-33−/− mice. a Static lung compliance (Cst) values in WT and IL-33−/− mice on day 21 after 
intratracheal instillation of PPE or saline. Mice received 2 U of PPE or saline by intratracheal instillation. Cst values were obtained as described 
in Materials and Methods. WT PBS: WT mice treated with PBS. IL-33−/− PBS: IL-33−/− mice treated with PBS. WT PPE: WT mice treated with PPE. 
IL-33−/− PPE: IL-33−/− mice treated with PPE. Data are shown as the mean ± SEM (n = 5–10 in each group). *P < 0.05 compared to WT PBS; #P < 0.05 
compared to WT PPE. b Representative images of H&E-stained lung tissue (magnification: × 200) (a) WT mice treated with PBS on (i) day 7, (ii) day 
14, and (iii) day 21, (b) IL-33−/− mice treated with PBS on (i) day 7, (ii) day 14, and (iii) day 21, (c) WT mice treated with PPE on (i) day 7, (ii) day 14, 
and (iii) day 21, (d) IL-33−/− mice treated with PPE on (i) day 7, (ii) day 14, and (iii) day 21. c Mean linear intercept (Lm) alveoli values. Morphometric 
assessment was performed on days 7, 14, and 21 after instillation. Lm values were determined as described in the “Materials and methods”. Data are 
shown as the mean ± SEM (n = 5–10 in each group). *P < 0.05 compared to WT PBS; **P < 0.05 compared to IL-33−/− PBS; #P < 0.05 compared to WT 
PPE
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between PPE-treated IL-33−/− and WT mice in the num-
ber of macrophages or neutrophils in BAL fluid. Instead, 
the level of HGF, which protects against the development 
of emphysema, was significantly lower in IL-33−/− mice 
compared to WT mice following PPE instillation. These 
observations suggested that loss of IL-33 may enhance 
the development of elastase-induced and CSE-induced 
emphysematous changes.
IL-33 is a cytokine that induces a Th2 cell immune 
response via ILC2s [7]. On the other hand, in the patho-
genesis of COPD, IL-33 may mainly affect macrophages 
and NK cells, because it has been reported that CS 
reduces the expression of ST2 on ILC2s and increases 
its expression on macrophages and NK cells [10]. In the 
present study, the levels of IL-33 in the lung were sig-
nificantly increased following PPE instillation, but the 
number of ILC2s in the lung was not increased by PPE 
treatment when the level of IL-33 in the lung reached its 
peak. These observations suggested that IL-33 did not 
affect ILC2s in our model.
The accumulation of inflammatory cells, including 
neutrophils, macrophages, and  CD8+ T cells, along 
with proteinase/anti-proteinase imbalance, apoptosis, 
and oxidative stress, may play an important role in the 
pathogenesis of COPD [30]. Neutrophils, which secrete 
MMP-9, cathepsin G, and neutrophil elastase, are pre-
dictors of disease severity with respect to the emphyse-
matous component of COPD [31]. Human MMP-9 was 
Fig. 3 Cell composition in BAL fluid on days 2, 7, 14, and 21 after PPE treatment. a Experimental protocol. Numbers of b total cells, c macrophages, 
d neutrophils, e lymphocytes, and f eosinophils. The results for each group are shows as the mean ± SEM; n = 5–10 in each group. *P < 0.05 
compared to WT PBS; #P < 0.05 compared to WT PPE
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shown to induce emphysema in a murine model [32], 
and MMP-9/TIMP-1 imbalance was observed in patients 
with COPD [33]. These observations suggest that con-
trolling neutrophilic inflammation and MMPs may pre-
vent the progression of emphysema. IL-33 expression 
is induced by exposure to CS in bronchial endothelial 
cells, and may in turn induce the expression of IL-6 and 
IL-8 [9]. Treatment with anti-IL-33 antibody has been 
reported to inhibit CS-induced airway inflammation 
[11]. These observations suggest that IL-33 may play an 
important role in the development of CS-induced airway 
inflammation. In the present study, however, IL-33 defi-
ciency did not affect PPE-induced neutrophilic airway 
inflammation. The levels of neutrophilic chemoattract-
ants, such as KC and MCP, were lower in IL-33−/− mice 
compared to WT mice following PPE instillation. These 
observations suggest that although partial loss of IL-33 
could attenuate airway inflammation, as reported previ-
ously [10, 11], complete loss of IL-33 does not improve 
the proteinase/anti-proteinase imbalance.
To further elucidate the mechanisms by which defi-
ciency of IL-33 exacerbates emphysematous changes 
Fig. 4 Cytokine and chemokine levels in BAL fluid on days 2, 7, 14, and 21 after PPE treatment. a KC, b MCP-1, c MIP-2, d MM-9, e HGF, and f VEFG. 
The results for each group are shows as the mean ± SEM; n = 4–6 in each group. *P < 0.05 compared to WT PBS. †P < 0.05 compared to  IL33−/− PBS; 
#P < 0.05 compared to WT PPE
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in the lung, we assessed lung-protective factors. It has 
been reported that VEGF and HGF protect against the 
development of emphysema. HGF recruited stem cells 
into injured tissue and induced their differentiation into 
tissue-specific cells [34]. Treatment with HGF reversed 
lung emphysema, possibly through stem cell mobilization 
and alveolar regeneration [3, 4]. Our data showed that 
the level of HGF in BAL fluid was significantly increased 
in PPE-treated WT and  IL33−/− mice compared to PBS-
treated mice, and the increase in HGF level in PPE-
treated  IL33−/− mice was less persistent compared to that 
in PPE-treated WT mice. In addition, administration of 
rIL-33 increased the levels of HGF in BAL fluid of PPE-
instilled mice. These data suggest that IL-33 may protect 
against the development of elastase-induced emphysema 
via HGF expression. It has also been reported that loss 
of VEGF amplified the IL-33-mediated inflammatory 
response [35]. Inhibition of VEGF decreased alveolariza-
tion and induced alveolar septal cell apoptosis, but did 
not inhibit lung cell proliferation [6, 36, 37]. In the pre-
sent study, however, VEGF levels in the lungs were not 
different between IL-33−/− and WT mice following instil-
lation of PPE or CS; therefore, VEGF may not have been 
affected in our emphysema models.
This study had some limitations. First, although IL-33-
/- mice displayed enhanced emphysematous changes, 
this only occurred when IL-33 was completely deficient. 
Treatment with anti-ST2 receptor antibody did not 
enhance emphysema development, suggesting that par-
tial IL-33 blockade is not sufficient to induce emphysema. 
Fig. 5 Number of ILC2s in the lung on day 7 after PPE treatment. The 
results for each group are shown as the mean ± SEM; n = 7 in each 
group. There was no significant difference in the number of ILC2s in 
the lung between PPE-treated WT mice and PPE-treated  IL33−/−mice
Fig. 6 Treatment of PPE-induced emphysema with recombinant 
IL-33. The mice received intraperitoneal injection of recombinant 
IL-33 (rIL-33) or PBS on days 0 and 3 following instillation of PBS or 
PPE. Lung function, lung histology, and morphometric measurements 
were performed 21 days as described in the Materials and Methods. 
a Cst values following treatment with rIL-33. b Lm values. Data are 
shown as mean ± SEM (n = 8 in each group). PBS/PBS: PBS-instilled 
mice treated with PBS. PPE/PBS: PPE-instilled mice treated with PBS. 
PPE/rIL-33: PPE-instilled mice treated with rIL-33. *P < 0.05 compared 
to PBS/PBS. There were no significant differences between PPE/PBS 
and PPE/rIL-33
Fig. 7 HGF and VEGF levels in BAL fluid of IL-33−/− mice following 
treatment with rIL-33. The IL-33−/− mice received intraperitoneal 
injection of rIL-33 or PBS on day 0 following instillation of PBS or 
PPE. BAL were performed on day 2, and levels of HGF and VEGF in 
BAL fluid were measured as described in the Materials and Methods. 
a HGF levels. b VEGF levels. Data are shown as the mean ± SEM 
(n = 5–8 in each group). IL-33−/− PBS PBS: PBS-instilled IL-33−/− mice 
treated with PBS. IL-33−/− PPE PBS: PPE-instilled IL-33−/− mice treated 
with PBS. IL-33−/− PPE rIL-33: PPE-instilled IL-33−/− mice treated with 
rIL-33. *P < 0.05 compared to IL-33−/− PBS PBS. #P < 0.05 compared to 
IL-33−/− PPE PBS
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Whether blockade of the IL-33-ST2 axis is harmful 
or beneficial for COPD in the clinical setting remains 
unclear. Second, treatment with IL-33 did not signifi-
cantly suppress emphysema development. However, 
modifications to the dose and timing of IL-33 administra-
tion may produce different outcomes. Thus, the effects of 
IL-33 supplementation for COPD remain unclear. Third, 
we have not assessed the CS-induced emphysema model, 
which more closely mimics human emphysema. We have 
shown that a congenital IL-33 defect might enhance 
elastase- and CSE-induced emphysema. Collectively, 
our results indicate that clinical manipulations of the IL-
33-ST2 axis may have varying effects on lung structure.
Conclusions
We demonstrated that the loss of IL-33 may enhance the 
development of emphysema. Our data suggested that 
although IL-33 may affect CS-induced airway inflam-
mation, complete loss of IL-33 may enhance emphysema 
and potentially be harmful in patients with COPD.
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